Enzyme

EQS-News: 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24

Retrieved on: 
Mercredi, mars 13, 2024

Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.

Key Points: 
  • Adriaan Moelker, CEO BRAIN Biotech AG, states: “Our BioScience segment made a very strong start to the business year.
  • The BRAIN Biotech Holding segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities.
  • CFO at BRAIN Biotech AG, Michael Schneiders, takes an optimistic view on the financial year 2023/24: “We aim to continue our organic growth path from the last two years.
  • The BRAIN Biotech Group now targets a revenue range of € 58 million to € 62 million for the new financial year.

MHI Thermal Systems to Launch 31 Models of Residential-use Air-Conditioners for the Japanese Market in 2024

Retrieved on: 
Lundi, mars 11, 2024

- Two types of sensors, and functions using ions and ozone provide comfort and cleanliness (S Series / SK Series)

Key Points: 
  • - Two types of sensors, and functions using ions and ozone provide comfort and cleanliness (S Series / SK Series)
    TOKYO, Mar 11, 2024 - (JCN Newswire) - Mitsubishi Heavy Industries Thermal Systems, Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, will launch 31 new models of residential-use air-conditioners for the Japanese market for 2024.
  • The new models in five series will be released starting April 1.
  • Together these new models provide comfortable living spaces for diverse lifestyles.
  • In addition, the AI learns how the room cools and warms, and adjusts automatically for comfortable and energy-saving operation.

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on: 
Lundi, mars 11, 2024

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points: 
  • The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
  • A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
  • It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
  • Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of  prasinezumab, which targets non-nitrated α-synuclein.

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Vendredi, mars 8, 2024

The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.

Key Points: 
  • The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
  • Announced leadership changes and strategic advisory engagement:
    Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023.
  • With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role.
  • Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Mercredi, février 28, 2024

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • Including enzyme sales related to PAXLOVID™, total revenues were $26.6 million in fourth quarter 2023 compared to $30.4 million in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product revenues were $18.1 million in fourth quarter 2023 compared to $23.3 million in fourth quarter 2022.
  • Product gross margin, excluding enzyme sales related to PAXLOVID™, was 71% for fourth quarter 2023 compared to 44% in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product gross margin for fourth quarter 2023 was 84% compared to 64% in fourth quarter 2022.

DepYmed to Meet with Investors at the BIO CEO and Investor Conference

Retrieved on: 
Mercredi, février 21, 2024

FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

Key Points: 
  • FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.
  • Today the Company announces that management will be meeting with investors at the BIO CEO and Investor Conference held on February 26 – 27, 2024 at the New York Marriott Marquis.
  • CEO Andreas Grill will be available for one-on-one meetings throughout the conference.

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Mardi, février 20, 2024

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

Retrieved on: 
Lundi, mars 4, 2024

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.
  • The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
  • Mr. Ahlstedt’s presentation will highlight recent technical developments, and upcoming milestones, on the company’s proprietary enzymatic RNA oligonucleotide synthesis technology, as part of the Innovation in Manufacturing session at the event.
  • This community, from the beginning, has been supportive of our mission to deliver sustainable RNA at scale.

Mānuka Health, Global Leader in Mānuka Honey, Launches Three Product Collections Designed for Holistic Inner and Outer Wellbeing

Retrieved on: 
Jeudi, mars 7, 2024

AUCKLAND, N.Z., March 7, 2024 /PRNewswire/ -- Mānuka Health, a global leader in premium mānuka honey products, is excited to announce the launch of three new product collections, inclusive of the brand's first skincare range. As the first prestige beauty and wellness brand to masterfully capture the complete spectrum of benefits from raw mānuka honey, propolis, and royal jelly, these new collections present one harmonious system designed to elevate vitality, reinforce resilience, and inspire complete wellbeing.

Key Points: 
  • Mānuka Health's new collections mirrors the intricate relationship between the European Honeybee pollinating amidst the blooms of the New Zealand mānuka tree.
  • The brand harvests their raw mānuka honey from the rich soils of New Zealand with brand-owned hives that ensure the utmost purity and quality.
  • Their unparalleled potency, individually and together, supports simplicity in a daily wellbeing routine for inner harmony and outer radiance.
  • All Mānuka Health's MGO mānuka honey is certified for authenticity, sustainably sourced, GMO-free, and raw and unpasteurized for exceptional benefits.

Survey Finds 49% of Americans Resolve to Eat More Protein in 2024

Retrieved on: 
Lundi, mars 4, 2024

NEW YORK, March 4, 2024 /PRNewswire/ -- This March marks the 44th year that Americans will observe National Nutrition Month®, a campaign from the Academy of Nutrition and Dietetics focusing on the importance of making informed food choices and developing sound eating and physical activity habits.

Key Points: 
  • This year, almost half of U.S. adults—49%—are resolving to eat more protein, per survey findings from a December 2023 consumer poll conducted by Harris Poll and 1440 Foods.
  • Yet, according to award-winning registered dietitian Toby Amidor, most American adults already consume enough daily protein—they're just doing it wrong.
  • According to Amidor, an advisor and partner to lifestyle nutrition line Pure Protein , most adults should aim for about 20-30 grams of protein per sitting to maximize protein synthesis and choose snacks that provide around 10-15 grams of protein to help curb hunger and meet their daily nutritional goals.
  • To view the full portfolio of Pure Protein powders, bars, shakes, and snacks, visit www.pureprotein.com or follow Pure Protein on Instagram at @officialpureprotein for recipes and tips.